Clinical Trials in China / NCT06762717
Active, not recruiting
Observational
FARAPULSE™ Pulsed Field Ablation System
NCT06762717 · tracked via the Priya Life Science China tracker
Condition(s) studied
Paroxysmal AF
Investigational drug(s) / intervention(s)
FARAPULSE™ Pulsed Field Ablation system
FARAPULSE™ Pulsed Field Ablation system: no intervention design in the study
Study summary
To obtain real world data on the use of, and provide continued evidence on safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) system when used per hospitals' standard of care in Chinese population.
Eligibility
Inclusion Criteria:
1. Subjects intended to be treated with the FARAPULSE™ Pulsed Field Ablation system for cardiac tissue ablation, per physician's medical judgement, and as per hospitals' standard of care
2. Subjects who are willing and capable of providing informed consent
3. Subjects who are willing and capable of participating in all testing associated with this clinical study at an approved clinical investigational center
4. Subjects whose age is 18 years or above.
Exclusion Criteria:
1. Subjects with a current interatrial baffle or patch
2. Subjects with a known or suspected atrial myxoma
3. Subjects with a myocardial infarction within 14 days prior to enrollment
4. Subjects with a recent (within 30 days prior to enrollment) Cerebral Vascular Accident (CVA)
5. Subjects who do not tolerate anticoagulation therapy
6. Subjects with an active systemic infection \*
7. Subjects with a presence of atrial known thrombus \*
8. Subjects with a known inability to obtain vascular access
9. Subjects who are pregnant or planning to be pregnant
10. Subjects with atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes
11. Subjects with any prosthetic heart valve, ring or repair including balloon aortic valvuloplasty
12. Subjects with a contraindication to an invasive electrophysiology procedure where insertion or manipulation of a catheter in the cardiac chambers is deemed unsafe per physician's medical judgement, such as, but not limited to, a recent previous cardiac surgery (e.g., ventriculotomy or atriotomy, CABG, PTCA/PCI/coronary stent procedure), recent previous unstable angina and/or in patients with congenital heart disease where the underlying abnormality increases the risk of the ablation (e.g., severe rotational anomalies of the heart or great vessels)
13. Subjects with a life expectancy of ≤ 1 year per investigator's opinion
14. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be brought to the attention of the sponsor to determine eligibility.
Primary outcome measure(s)
- Failure-free rate — 12 Months
Failure-free rate at 12 Month post index procedure. - Device-or procedure-related SAEs: — 7 days and 12 months
Composite of the following device- or procedure-related SAEs: - Procedure- and device related adverse events — 12 Months and 2 years and 3 years
All FARAPULSE™ PFA procedure- and device related adverse events at 12 Month, 2 Year and 3 Year follow-up.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Fuwai Hospital, Chinese Academy of Medical Sciences | Beijing | China/Beijing |
More Boston Scientific Corporation trials in China
IT Matters: The Erectile Restoration Registry
Enrolling by invitation
A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China
Active, not recruiting
Intra-operative Pancreatoscopy in Patients With IPMN
Active, not recruiting
Other trials for the same condition
3-Dimensional Mapping System: The PULSTAR II Study
Active, not recruiting
PulseMagic™ TrueForce™ PAF NMPA Study
Starting soon
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06762717 on ClinicalTrials.gov ↗ ← All trials in China